| Identification | Back Directory | [Name]
5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI) | [CAS]
604769-01-9 | [Synonyms]
CS-1048
R 306465
JNJ 16241199
R306465(JNJ-16241199)
JNJ-16241199; JNJ16241199; JNJ 16241199
R 306465;JNJ16241199;R-306465;JNJ 16241199
N-Hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]-5-pyrimidinecarboxamide
N-hydroxy-2-[4-(naphthalen-2-ylsulfonyl)piperazin-1-yl]pyriMidine-5-carboxaMide
5-PyriMidinecarboxaMide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]-
5-Pyrimidinecarboxamide, N-hydroxy-2-[4-(2-naphthalenylsulfonyl)-1-piperazinyl]- (9CI)
2-[4-(Naphthalene-2-sulfonyl)-piperazin-1-yl]-pyrimidine-5-carboxylic acid hydroxyamide | [Molecular Formula]
C19H19N5O4S | [MDL Number]
MFCD13186898 | [MOL File]
604769-01-9.mol | [Molecular Weight]
413.45 |
| Hazard Information | Back Directory | [Uses]
JNJ-16241199 (R306465) is an orally active, selectivehydroxamate-based histone deacetylase (HDAC) inhibitor, with theIC50of 3.3 nM and 23 nM for HDAC1and HDAC8, respectively.JNJ-16241199induces histone 3 acetylation and strongly increases
the expression of p21waf1, cip1 in A2780 ovarian carcinoma cells.JNJ-16241199 inducescell apoptosisand shows anticancer activityin a broad spectrum of human malignancies. JNJ-16241199 can be used for cancer study[1]. | [in vivo]
JNJ-16241199 (R306465) inhibits proliferation in acute lymphoblastic leukaemia (ALL), AML, chronic lymphoblastic leukaemia (CLL), chronic myeloid leukaemia (CML), lymphoma and myeloma tumour cells (IC50 values = 15–486 nM) [1].
JNJ-16241199 inhibits the primary human mammary epithelial cell (HMEC) proliferation with the IC50 of 32 nM, and is insensitive to quiescent, non-proliferative HMEC cells (IC50 = 7815 nM) [1].
JNJ-16241199 (0.1, 0.3, 1 μM, 24-48 h) induces apoptosis and inhibits angiogenesis in A2780 cell line[1]. | Animal Model: | Human A2780, H460 and HCT116 orthotopic xenograft tumor models[1] | | Dosage: | 10-40 mpk/day for 28 days | | Administration: | Oral gavage (p.o.) | | Result: | Induced H3 acetylation and p21waf1, cip1 promoter activity in A2780 ovarian tumour tissue.
Decreased tumour volume in three orthotopic xenograft tumor models.
Reached maximal decrease in final tumour volume to 76–87% in human A2780 orthotopic xenograft tumor models.
|
| [IC 50]
HDAC1: 3.3 nM (IC50); HDAC8: 23 nM (IC50) | [References]
[1] Arts J, et al. R306465 is a novel potent inhibitor of class I histone deacetylases with broad-spectrum antitumoral activity against solid and haematological malignancies. Br J Cancer. 2007;97(10):1344-1353. DOI:10.1038/sj.bjc.6604025 |
|
| Company Name: |
Cckinase, Inc.
|
| Tel: |
+1 (732)236-3202 |
| Website: |
www.cckinase.com |
|